Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 15;265(1-2):82-90.
doi: 10.1016/j.jneuroim.2013.10.003. Epub 2013 Oct 12.

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro

Li Li  1 , Jingchun Liu, Thomas Delohery, Donghui Zhang, Christopher Arendt, Catherine Jones
Affiliations

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro

Li Li et al. J Neuroimmunol. .

Abstract

Teriflunomide is an inhibitor of dihydro-orotate dehydrogenase (DHODH), and is hypothesized to ameliorate multiple sclerosis by reducing proliferation of stimulated lymphocytes. We investigated teriflunomide's effects on proliferation, activation, survival, and function of stimulated human peripheral blood mononuclear cell subsets in vitro. Teriflunomide had little/no impact on lymphocyte activation but exerted significant dose-dependent inhibition of T- and B-cell proliferation, which was uridine-reversible (DHODH-dependent). Viability analyses showed no teriflunomide-associated cytotoxicity. Teriflunomide significantly decreased release of several pro-inflammatory cytokines from activated monocytes in a DHODH-independent fashion. In conclusion, teriflunomide acts on multiple immune cell types and processes via DHODH-dependent and independent mechanisms.

Keywords: Anti-inflammatory; Anti-proliferative; CNS; De novo pyrimidine synthesis; Immunomodulation; Multiple sclerosis.

PubMed Disclaimer

Publication types